Tirzepatide (weekly injectable) Dosing frequency: Once weekly, same day each week Half-life: approximately 5 days (120 hours) Peak concentration: 8 to 72 hours after injection Recommended timing approach: The shorter half-life compared to semaglutide means the end-of-week trough is more noticeable
By unifying three incretinmetabolic pathways, it is being studied for multidimensional effects on appetite, glycemic control, energy expenditure, and body composition
Avenell, A., Richmond, P
Ideal Candidates Sofwave is an excellent choice for adults who: Are in their mid-30s or older experiencing mild to moderate skin laxity Notice fine lines, wrinkles, or loss of firmness in the face or neck Want to address early signs of aging before they become more pronounced Prefer non-surgical alternatives to facelift surgery Have realistic expectations for gradual, natural-looking improvement Want to maintain or enhance results from previous surgical procedures Have darker skin tones that may not be candidates for certain laser treatments Sofwave is not recommended for those who: Have open wounds or active acne in the treatment area Have a pacemaker or electronic implants in the treatment area Are pregnant, nursing, or have given birth within the past three months Have severe skin laxity that would be better addressed surgically During your consultation, well discuss your medical history and determine if Sofwave is appropriate for your individual needs

When tirzepatide activates these receptors, it may alter dopamine and serotonin signaling pathways that influence mood and anxiety perception
But costs are becoming prohibitive